Hepatoid adenocarcinoma of the lung with PD-L1 expression and the response to anti-PD-1 therapy: a case report

被引:1
|
作者
Li, Yan [1 ]
Liu, Lili [2 ]
Wang, Dongfeng [3 ]
Tan, Xiaojing [1 ]
Sui, Yanmin [1 ]
Yang, Honglan [1 ]
机构
[1] Dongying Peoples Hosp, Dept Oncol, Dongying, Shandong, Peoples R China
[2] Dongying Peoples Hosp, Dept Pathol, Dongying, Shandong, Peoples R China
[3] Dongying Peoples Hosp, Dept Chest Surg, Dongying, Shandong, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
hepatoid adenocarcinoma of the lung; alpha-fetoprotein; anti-PD-1; therapy; brain metastases; case report;
D O I
10.3389/fonc.2023.1257931
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatoid adenocarcinoma of the lung (HAL) is extremely rare; a standardized treatment strategy for HAL has not been established. The prognosis of patients with unresectable HAL is extremely poor. Here, we reported a 64-year-old male patient with unresectable alpha-fetoprotein-producing HAL who showed moderate harboring programmed death ligand 1 (PD-L1) expression and no targetable driver mutations. The patient was treated with brain radiotherapy, multiple lines of chemotherapies, and PD-1 inhibitor and achieved a survival rate of 9 months. The patient finally died because of the progression of brain metastasis. The case report provides valuable information for the treatment strategy development of advanced HAL patients and reminds us of the therapeutic particularity of brain metastasis.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy
    Mei, Jie
    Cai, Yun
    Wang, Huiyu
    Xu, Rui
    Zhou, Jiaofeng
    Lu, Jiahui
    Yang, Xuejing
    Pan, Jiadong
    Liu, Chaoying
    Xu, Junying
    Zhu, Yichao
    CLINICAL IMMUNOLOGY, 2023, 246
  • [32] PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas
    Perottet, Jeremy
    Le Goff, Emeline
    Legoupil, Delphine
    Quere, Gilles
    Schick, Ulrike
    Marcorelles, Pascale
    Uguen, Arnaud
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (02) : 161 - 165
  • [33] Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
    Musaelyan, Aram A. A.
    Lapin, Sergey L. V.
    Urtenova, Margarita A. A.
    Odintsova, Svetlana V. V.
    Chistyakov, Ivan V. V.
    Ulitin, Andrey M. M.
    Akopov, Andrey L. L.
    Orlov, Sergey V. V.
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (03)
  • [34] Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
    Zhang, Chaoxu
    Fan, Yibo
    Che, Xiaofang
    Zhang, Min
    Li, Zhi
    Li, Ce
    Wang, Shuo
    Wen, Ti
    Hou, Kezuo
    Shao, Xinye
    Liu, Yunpeng
    Qu, Xiujuan
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [35] Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer
    Shukuya, Takehito
    Carbone, David P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 976 - 988
  • [36] Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
    Wang, Luyao
    Ma, Qingxia
    Yao, Ruixue
    Liu, Jia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 79
  • [37] Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
    Shah, Shalin
    Wood, Kevin
    Labadie, Brian
    Won, Brian
    Brisson, Ryan
    Karrison, Theodore
    Hensing, Thomas
    Kozloff, Mark
    Bao, Riyue
    Patel, Jyoti D.
    Luke, Jason J.
    ONCOTARGET, 2018, 9 (04) : 4375 - 4384
  • [38] Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression
    Wang, Shu Shi
    Liu, Ye
    Zhang, Xuan Ting
    Yu, Dong Qiang
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 260 (01): : 63 - 73
  • [39] Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy
    Cao, Yiyi
    Li, Wenbo
    Wang, ZhengJie
    Pang, Hua
    TUMORI JOURNAL, 2021, 107 (04): : 282 - 291
  • [40] Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
    Chen, Lieping
    Han, Xue
    JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09): : 3384 - 3391